A surge in short-term call option activity for Advanced Micro Devices (AMD) suggests some investors are positioning for a swift recovery, despite the stock's sharp 16% drop following strong quarterly results.
Boston Scientific's robust Q4 results were overshadowed by investor disappointment over its forward guidance, triggering a sharp sell-off and raising questions about market expectations for high-flying medtech stocks.
Shares of Eli Lilly surged nearly 10% after the pharmaceutical giant smashed fourth-quarter estimates and issued a bullish 2026 outlook, powered by unprecedented demand for its GLP-1 drugs Mounjaro and Zepbound.
As Amazon prepares to release its fourth-quarter results, investors are scrutinizing its massive capital expenditure plans for AI against a backdrop of cost-cutting and mixed signals from Big Tech peers.
IBM's latest quarterly results showcase robust revenue growth and expanding margins, reinforcing a bullish thesis centered on its strategic pivot to a software-first, AI-integrated platform. With disciplined execution and a clear growth trajectory, the tech giant is making a case for a sustained rerating.
Cloud communications firm 8x8 (EGHT) surged over 43% after posting Q4 results that handily topped analyst forecasts, fueled by robust demand for its AI-powered customer experience platform and an upbeat revenue outlook.
Shares of Columbia Sportswear (COLM) soared over 13% after the outdoor apparel giant posted better-than-expected Q4 results and issued an optimistic full-year profit forecast, signaling a potential turnaround after a period of market skepticism.
Eli Lilly & Co. shares surged 10% after the pharmaceutical giant posted Q4 2025 results that smashed analyst forecasts and issued a robust 2026 outlook, powered by unprecedented demand for its GLP-1 drugs Mounjaro and Zepbound.
MGM Resorts International stock surged more than 11% after its sports betting joint venture, BetMGM, reported a dramatic swing to profitability and issued a bullish forecast, signaling a major inflection point for the digital venture.
Azenta's stock tumbled sharply after its Q4 results revealed a significant shortfall in a key profitability metric, despite revenue meeting expectations, sparking a major sell-off.
Enphase Energy's latest quarterly results and bullish 2026 outlook have reignited investor interest, sparking a sharp rally. However, the microinverter leader's path forward is clouded by sector headwinds and a stark contrast between recent gains and steep annual losses.
NGL Energy Partners (NGL) reported robust quarterly results, featuring record water disposal volumes and significant adjusted EBITDA growth. The partnership's units have surged over 20% in the past month, prompting investors to question if the stock still holds value after its impressive run.
Japanese pharmaceutical giant Shionogi reports robust nine-month results, driving a significant share price surge. As the stock trades above some analyst targets yet below intrinsic value estimates, investors are weighing whether the momentum has run its course or if there's still room to grow.
Despite posting quarterly results that exceeded analyst expectations, shares of Boston Scientific and AbbVie fell sharply as investors scrutinized underperformance in key business units and expressed caution over forward-looking statements.
As Alphabet prepares to report its fourth-quarter results, investors are watching to see if the tech giant's AI investments can sustain its recent stock surge and justify its massive capital expenditures.
As Arm Holdings prepares to report its Q3 FY2026 results, the semiconductor design giant stands at a crossroads. Investors are looking beyond recent stock volatility for signs that its licensing momentum and AI strategy can justify a premium valuation in a choppy market.
The iBuying pioneer's stock retreated last month, reflecting broader market caution and the persistent challenges of a tight, high-rate housing environment, despite a recent leadership overhaul and strategic pivot.
Barclays raises its price target on Amphenol Corporation (APH) to $175, arguing a recent stock pullback offers an attractive entry point following solid Q4 results and a major acquisition.
SanDisk shares are in focus after Barclays dramatically raised its price target following the company's better-than-expected quarterly results and its recent corporate separation. The move echoes bullish sentiment from other major banks.
Amgen pushes back against regulators seeking to pull a key drug, while Pfizer faces investor skepticism over its obesity candidate. Meanwhile, Merck details an ambitious plan to offset the looming patent cliff of its blockbuster Keytruda and reach $70 billion in annual sales.
